Jin-bo Li, Li-Hong Zhang, Chang-Sen Leng, Jun-Ying Chen, Jian-Hua Fu
{"title":"Modification of Pathological Nodal Classification for pT1b Esophageal Squamous Cell Carcinoma With Lymphovascular Invasion: Over 10-Year Experience","authors":"Jin-bo Li, Li-Hong Zhang, Chang-Sen Leng, Jun-Ying Chen, Jian-Hua Fu","doi":"10.1002/cnr2.70342","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Lymphovascular invasion (LVI) adversely affects the survival of pT1b esophageal squamous cell carcinoma (ESCC). It is hypothesized that a modified stage classification of pT1b ESCC based on LVI may facilitate multidisciplinary therapy in LVI-positive patients.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>The study aims to investigate the impact of LVI on pathological nodal classification for pT1b ESCC.</p>\n </section>\n \n <section>\n \n <h3> Methods and Results</h3>\n \n <p>Surgically resected pT1b ESCC patients in Sun Yat-sen University Cancer Center between 2008 and 2018 were retrospectively reviewed. Tumor sections were re-assessed for LVI by gastrointestinal pathologists. The associations between patient survival and LVI were evaluated by the Log-rank method. A multivariate Cox regression model was applied to identify the impact of LVI on survival. Prognostic performance was assessed by Harrell's <i>C</i>-index. A total of 424 cases with the pT1b stage were included. The risk of LVI was significantly higher in patients with nodal positive status (<i>p</i> < 0.001) and larger tumor size (<i>p</i> = 0.033). The 5-year OS for LVI+ patients were 50.3% versus 78.0% for LVI− (<i>p</i> < 0.001). Multivariable analyses suggested that LVI (<i>p</i> = 0.021) and pN (<i>p</i> = 0.016) stages were two independent adverse prognostic factors in pT1b patients. When classifying LVI+ as an independent subgroup into the pN category, the modified pN staging system demonstrated a superior prognostic performance (<i>p</i> < 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Tumors with LVI should be defined as a separate subclassification to accurately classify the prognostic category in pT1b patients. Further studies are required to investigate multidisciplinary therapies for LVI+ pT1b patients.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70342","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Lymphovascular invasion (LVI) adversely affects the survival of pT1b esophageal squamous cell carcinoma (ESCC). It is hypothesized that a modified stage classification of pT1b ESCC based on LVI may facilitate multidisciplinary therapy in LVI-positive patients.
Aims
The study aims to investigate the impact of LVI on pathological nodal classification for pT1b ESCC.
Methods and Results
Surgically resected pT1b ESCC patients in Sun Yat-sen University Cancer Center between 2008 and 2018 were retrospectively reviewed. Tumor sections were re-assessed for LVI by gastrointestinal pathologists. The associations between patient survival and LVI were evaluated by the Log-rank method. A multivariate Cox regression model was applied to identify the impact of LVI on survival. Prognostic performance was assessed by Harrell's C-index. A total of 424 cases with the pT1b stage were included. The risk of LVI was significantly higher in patients with nodal positive status (p < 0.001) and larger tumor size (p = 0.033). The 5-year OS for LVI+ patients were 50.3% versus 78.0% for LVI− (p < 0.001). Multivariable analyses suggested that LVI (p = 0.021) and pN (p = 0.016) stages were two independent adverse prognostic factors in pT1b patients. When classifying LVI+ as an independent subgroup into the pN category, the modified pN staging system demonstrated a superior prognostic performance (p < 0.001).
Conclusion
Tumors with LVI should be defined as a separate subclassification to accurately classify the prognostic category in pT1b patients. Further studies are required to investigate multidisciplinary therapies for LVI+ pT1b patients.